MedTrace Logo

A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole

NCT03314298 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-04-18

No results posted yet for this study

Summary

A single dose trial to evaluate the pharmacokinetics of testosterone and anastrozole from subcutaneous testosterone and anastrozole (T+Ai) in premenopausal women

Conditions

  • Mammographic Density

Interventions

DRUG

testosterone anastrozole

subcutaneous testosterone and anastrozole

Sponsors & Collaborators

  • Havah Therapeutics Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Stephen N Birrell, Md PhD · Wellend Health

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2018-04-17
Completion
2018-04-17

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03314298 on ClinicalTrials.gov